
Lilly and EVA Pharma Partner to Increase Baricitinib Availability in Low- and Middle-Income Countries
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income countries in Africa by 2030. Developed by Incyte and licensed…













